• Entitled “Release blockbusters over time”, the study by Portzamparc – BNP Paribas Group recommends the purchase price with a target price of 14.4 euros per share.
• This new coverage comes as the first product based on MedinCell’s long-acting injectable technology is expected to be marketed in the United States in the first half of 2023 (subject to FDA approval); two other products are in phase 3, and several others in development.
• MedinCell recently obtained ISS ESG “Prime” status for its performance in terms of sustainable development, thus positioning itself among the 10% of the most virtuous companies in the pharmaceutical and biotechnology industry.
• MedinCell is also followed by Bryan Garnier, Kepler Cheuvreux, ODDO-BHF and TP ICAP
To receive all of MedinCell’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.